Tryton Medical Inc. officials announce that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options in bifurcations in large vessels with a short main branch landing zone. The Tryton Side Branch SHORT Stent length is 15 mm, or 3mm shorter in the main branch zone than the standard Tryton Side Branch Stent. The company is launching the product immediately in CE Mark countries. This innovation leverages the company's proprietary, first-in-class Tri-ZONE technology and adds to the Tryton family of stents.
Joanna J. Wykrzykowska, M.D., Ph.D., from the Academic Medical Center, University of Amsterdam, Netherlands completed the first implant of the Tryton Side Branch SHORT Stent. “The Tryton Side Branch SHORT Stent is an important advance in coronary stents. It gives me the control I need to treat patients who present with significant disease in a large, bifurcated vessel and whose anatomy in the main branch makes it challenging to deliver a longer size stent, ” said Dr. Wykrzykowska.
Dr. Wykrzykowska continues, “The Tryton Side Branch SHORT Stent may be particularly helpful when treating disease in the left main artery. Left main coronary artery disease has historically been challenging to address interventionally, but this new stent provides confidence I can deliver it where it needs to go and ensure both the main branch and side branch openings receive optimum scaffolding and support.”
“Interventional cardiologists told us they would value a dedicated bifurcation stent designed to work in their more challenging patients. The Tryton Side Branch SHORT Stent was developed in response to this request,” states Shawn McCarthy, CEO of Tryton Medical. “We are pleased we were able to quickly and effectively iterate our stent design, secure regulatory approval and bring doctors the confidence and control they expect from Tryton, optimized for more complex bifurcations.”